Lung Cancer

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.

Raja Mudad, MD, FACP, discussed the available EGFR inhibitors and sequencing challenges for patients with EGFR-mutant non-small cell lung cancer.

Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.

Luis E. Raez, MD, discusses major trials in squamous NSCLC and what lies ahead for immunotherapy.

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.